Andrew Pierce
Company: Crescendo Biologics
Job title: Vice President - Translational Biology
Seminars:
Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another 9:30 am
What are the key learnings and questions that have come out of the RELATIVITY-047 Trial? How do we rationally test PD-1/LAG-3 combinations in a way that further elucidates their interplay with one another? Will our understanding grow more in vivo with mice, or in the clinic?Read more
day: Day Two
Primary Pharmacology of CB213, a LAG-3-PD1 Co-targeting Humabody™ 2:00 pm
CB213 is engineered to engage LAG-3 particularly on PD1 expressing cells Human ex vivo and mouse syngeneic in vivo studies illustrate CB213 anti-tumor activity Pharmacokinetics studies in non-human primates suggest weekly or biweekly clinical dosing of CB213Read more
day: Day One